Co-Diagnostics, Inc. to Launch Vector Control Products into Midwest US at OPMA Conference
September 19 2019 - 6:30AM
Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that it
will be hosting a booth and launching its vector control testing
products to the midwestern USA at the Oklahoma Pest Management
Association (OPMA) Conference in Tulsa, OK on September 19-20.
Over 1,000 mosquito abatement districts (MADs)
exist across the North American continent. Diseases such as West
Nile virus (WNV) are carried by migratory birds or other vectors,
and are then transmitted to humans or livestock by mosquitoes. The
proliferation of the Aedes Aegypti and Asian Tiger (Aedes
albopictus) mosquitoes throughout the United States in recent
decades has led to the detection of certain mosquito-borne diseases
in every state in the continental US, including WNV. MADs provide
front-line defense in controlling mosquito populations to prevent
the spread of WNV and other diseases like Western Equine
Encephalitis (WEE) and Eastern Equine Encephalitis (EEE), the
latter of which has recently been identified in several states in
the Eastern US.
The Company has already begun equipment
installations and commenced sales to MADs across the country, and
their presence at OPMA coincides with the recent launch of their
Vector Smart™ North American Mosquito-West (NAM-w) test and
initiation of sales efforts in the Midwest US region.
“We are excited about the opportunities the OPMA
presents for Co-Diagnostics and our vector control products,”
remarked Dwight Egan, CEO of Co-Diagnostics. “It is impossible to
overstate the importance of accurate and effective mosquito
abatement programs, and all indications are that these well-funded
activities are only expected to increase in scope and scale.
Co-Diagnostics vector control tests provide accurate, efficient
detection of dangerous diseases carried in mosquito populations. We
are confident that MADs throughout the Midwest will benefit from
our products and that this conference will be instrumental in
growing our footprint across the region.”
About Co-Diagnostics,
Inc.:Co-Diagnostics, Inc., a Utah corporation, is a
molecular diagnostics company that develops, manufactures and
markets a new, state-of-the-art diagnostics technology. The
Company’s technology is utilized for tests that are designed using
the detection and/or analysis of nucleic acid molecules (DNA or
RNA). The Company also uses its proprietary technology to design
specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to
specific customers.
Forward-Looking Statements:
This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company’s balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities
laws.
Company Sales
Contact:
Seth
Egan
Head of International
Sales
+1 801-438-1036
#2
s.egan@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024